Patents by Inventor Steven R. Gullans
Steven R. Gullans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10183035Abstract: The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.Type: GrantFiled: October 26, 2017Date of Patent: January 22, 2019Assignee: CELLACT PHARMA GMBHInventors: Nalan Utku, Steven R. Gullans
-
Publication number: 20180042952Abstract: The present invention pertains to the use of podophyllotoxin derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.Type: ApplicationFiled: October 26, 2017Publication date: February 15, 2018Inventors: Nalan UTKU, Steven R. GULLANS
-
Patent number: 9827261Abstract: The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.Type: GrantFiled: March 12, 2014Date of Patent: November 28, 2017Assignee: CELLACT PHARMA GMBHInventors: Nalan Utku, Steven R. Gullans
-
Publication number: 20160022721Abstract: The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: Cellact Pharma GMBHInventors: Nalan UTKU, Steven R. GULLANS
-
Patent number: 8551700Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: GrantFiled: July 12, 2010Date of Patent: October 8, 2013Assignees: The Brigham and Women's Hospital, Inc., Wesleyan UniversityInventors: Gavin J. Gordon, Roderick V. Jensen, Steven R. Gullans, Li-Li Hsiao, Raphael Bueno
-
Patent number: 7931901Abstract: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described.Type: GrantFiled: August 25, 2006Date of Patent: April 26, 2011Assignees: The Brigham and Women's Hospital, Inc.Inventors: Nalan Utku, Steven R. Gullans, Edgar L. Milford
-
Publication number: 20110059854Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: ApplicationFiled: July 12, 2010Publication date: March 10, 2011Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., WESLEYAN UNIVERSITYInventors: GAVIN J. GORDON, RODERICK V. JENSEN, STEVEN R. GULLANS, LI-LI HSIAO, RAPHAEL BUENO
-
Patent number: 7863418Abstract: Described are a T cell immune response cDNA 7 (TIRC7) encoding a T-cell transmembrane protein, peptides and polypeptides derived therefrom and antibodies recognizing such (poly)peptides. Peptides, polypeptides and antibodies capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Vectors comprising polynucelotides encoding such polypeptides and peptides, host cells transformed therewith, and their use in the production of such, peptides or polypeptides are also described.Type: GrantFiled: May 10, 2005Date of Patent: January 4, 2011Assignees: The Brigham and Women's Hospital, Inc.Inventors: Nalan Utku, Steven R. Gullans, Edgar L. Milford
-
Patent number: 7622260Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: GrantFiled: September 5, 2002Date of Patent: November 24, 2009Assignees: The Brigham and Women's Hospital, Inc., Wesleyan UniversityInventors: Gavin J. Gordon, Roderick V. Jensen, Steven R. Gullans, Raphael Bueno, Li-Li Hsiao
-
Patent number: 7595159Abstract: The present invention identifies a number of gene markers whose expression is altered in neurodegenerative diseases (ND). These markers can be used to diagnose or predict ND in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent ND development or progression.Type: GrantFiled: November 3, 2005Date of Patent: September 29, 2009Assignee: The Brigham and Women's Hospital, Inc.Inventors: Clemens R. Scherzer, Steven R. Gullans, Roderick Jensen
-
Publication number: 20090104617Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: ApplicationFiled: December 5, 2008Publication date: April 23, 2009Applicants: The Brigham And Women's Hospital, Inc., Wesleyan UniversityInventors: Gavin J. Gordon, Roderick V. Jensen, Steven R. Gullans, Li-Li Hsiao, Raphael Bueno
-
Publication number: 20080103296Abstract: The invention relates to methods for analyzing and characterizing single polymers such as nucleic acid molecules. In preferred embodiments, the single molecules are analyzed using single molecule detection and analysis systems.Type: ApplicationFiled: March 19, 2007Publication date: May 1, 2008Applicant: U.S. Genomics, Inc.Inventors: Xiaojian David Zhao, Jeffrey D. Randall, Bijit Kundu, Jessica Kesty, Steven R. Gullans, Eugene Y. Chan, Martin Fuchs, Jenny E. Rooke
-
Patent number: 7282330Abstract: The invention relates to methods for analyzing and characterizing single polymers such as nucleic acid molecules. In preferred embodiments, the single molecules are analyzed using single molecule detection and analysis systems.Type: GrantFiled: February 5, 2004Date of Patent: October 16, 2007Assignee: U.S. Genomics, Inc.Inventors: Xiaojian (David) Zhao, Jeffrey D. Randall, Bijit Kundu, Jessica Kesty, Steven R. Gullans, Eugene Y. Chan, Martin Fuchs, Jenny E. Rooke
-
Publication number: 20040161794Abstract: The present invention relates to a method of identifying an agent (e.g., peptide, small molecule) that alters (partially, completely) the activity (function, expression) of HIF. In one embodiment, the method of identifying an agent that alters (e.g., inhibits, enhances) the activity of HIF comprises contacting a molecule in the HIF biosynthetic pathway (e.g., a precursor of HIF, such as a steroid precursor; an enzyme) with an agent to be assessed and determining whether the activity of the molecule (function, expression) is altered in the presence of the agent when compared to the activity of the molecule in the absence of the agent. The invention is also related methods of treatment using such agents; and methods of monitoring the biosynthetic pathway of OLC/HIF. In particular, the invention is related to agents, treatments, and diagnostics for diseases such as hypertension and heart failure.Type: ApplicationFiled: June 20, 2003Publication date: August 19, 2004Applicants: The General Hospital Corporation, Brigham and Women's Hospital Inc.Inventors: Garner T. Haupert, Steven R. Gullans
-
Publication number: 20040156826Abstract: The present invention identifies a number of gene markers whose expression is altered in multiple sclerosis (MS). These markers can be used to diagnose or predict MS in subjects, and can be used in the monitoring of therapies. In addition, these genes identify therapeutic targets, the modification of which may prevent MS development or progression.Type: ApplicationFiled: September 25, 2003Publication date: August 12, 2004Inventors: Fernando Dangond, Daehee Hwang, Steven R. Gullans
-
Publication number: 20030219760Abstract: The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided.Type: ApplicationFiled: September 5, 2002Publication date: November 27, 2003Applicant: The Brigham and Women's Hospital, Inc.Inventors: Gavin J. Gordon, Roderick V. Jensen, Steven R. Gullans, Raphael Bueno
-
Publication number: 20030124614Abstract: Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein (TIRC7) are provided. Furthermore, vectors comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins, peptides or polypeptides are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore described polynucleotide, vector, protein, peptide, polypeptide, or antibody. Furthermore, methods and uses for modulating immune responses through the novel TIRC7 membrane protein as well as pharmaceutical compositions comprising agents which act on the TIRC7 membrane protein or its ligand are described.Type: ApplicationFiled: May 13, 2002Publication date: July 3, 2003Applicant: Brighams and Womens Hospital Inc.Inventors: Nalan Utku, Steven R. Gullans, Edgar L. Milford
-
Publication number: 20030013692Abstract: The invention features a method for inhibiting neuronal cell death in a mammal by administering to the mammal a cytoprotective composition.Type: ApplicationFiled: January 18, 2002Publication date: January 16, 2003Inventors: Steven R. Gullans, Satinder Sarang
-
Patent number: 5773213Abstract: A method for conducting sequential nucleic acid hybridization steps is described, whereby the ability of earlier-used primers or probes to participate in subsequent hybridization steps can be minimized, even though the differences between primer lengths are relatively small. It also relates to a rapid and quantitative method for the sequential synthesis of polynucleotide sequences by using a plurality of oligonucleotide primers, with the earlier utilized primers causing a minimum of interference with the subsequent primed synthesis reactions, yet without the need for intermediate purification steps.Type: GrantFiled: June 6, 1994Date of Patent: June 30, 1998Assignee: Brigham & Women's HospitalInventors: Steven R. Gullans, Ryoji Kojima, Jeffrey Randall
-
Patent number: 5182299Abstract: A method of treating an osmotic disturbance in an animal which comprises administering to an animal an effective amount of an organic osmolyte, wherein the organic osmolyte is a polyol. Specific polyols include myo-inositol and sorbitol. Also included are precursors of organic osmolytes including precursors of polyols. Other polyol precursors are selected from the group consisting of glucose, glucose polymers, and glycerol. Also incluThis invention was funded by a research grant from the National Institutes of Health, 1RO1 DK36031, which provides to the United States Government certain rights in the invention.Type: GrantFiled: March 19, 1991Date of Patent: January 26, 1993Assignee: Brigham and Women's HospitalInventors: Steven R. Gullans, Charles W. Heilig